The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.
June 12th 2022
The phase 3 BRUIN CLL-313 trial is currently recruiting patients with treatment naïve chronic lymphocytic leukemia or small lymphocytic lymphoma to evaluate the efficacy and safety of pirtobrutinib monotherapy vs bendamustine plus rituximab.
June 11th 2022
Jeff Sharman, MD, discusses 5-year follow-up data from the phase 3 Elevate CLL TN trial in treatment-naïve patients with chronic lymphocytic leukemia.
June 11th 2022
Time-limited targeted therapy with venetoclax plus obinutuzumab with or without ibrutinib demonstrated superior progression-free survival outcomes compared with standard chemoimmunotherapy in patients with chronic lymphocytic leukemia.
June 10th 2022
Patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic leukemia assigned to zanubrutinib reported better health-related quality of life than those administered ibrutinib.
June 10th 2022
The fixed-duration, frontline combination comprised of ibrutinib and venetoclax continued to produce deep, durable responses with a clinically meaningful progression-free survival benefit in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
June 9th 2022
This publication highlights expert perspectives on the current therapeutic landscape in chronic lymphocytic leukemia with emphasis on factors affecting treatment selection including novel regimens, combination therapies, and ongoing clinical trials.
June 8th 2022
The BRUIN CLL-321 trial is evaluating pirtobrutinib monotherapy compared with investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously received covalent BTK inhibitor treatment.
June 4th 2022
At approximately 5 years of follow-up, findings from the phase 3 ELEVATE-TN study show that treatment outcomes are more favorable with acalabrutinib with or without obinutuzumab compared with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.
June 3rd 2022
Fixed-duration venetoclax plus rituximab has shown sustained progression-free survival, overall survival, and minimal residual disease benefits vs bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia, regardless of high-risk biomarkers.
June 2nd 2022
The fixed-duration combination of ibrutinib and venetoclax produced deep responses and improved progression-free survival vs chlorambucil plus obinutuzumab when used in previously untreated patients with chronic lymphocytic leukemia who were older and/or who had comorbidities, according to findings from the phase 3 GLOW trial.
June 2nd 2022
For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.
May 31st 2022
Nurix Therapeutics has initiated an ongoing phase 1 trial to examine NX-2127, an immunomodulatory oral BTK inhibitor, in patients with chronic lymphocytic leukemia.
May 29th 2022
Although lower fatality rates were reported during the omicron wave of the COVID-19 pandemic in patients with chronic lymphocytic leukemia, close monitoring and preemptive antiviral therapy is still recommended following a positive SARS-CoV-2 test, particularly in patients with close hospital contacts and those older than 70 years of age with at least one comorbidity.
May 23rd 2022
Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.
May 10th 2022
Richard R. Furman, MD, discusses current treatment options in chronic lymphocytic leukemia.
May 3rd 2022
Anthony Mato, MD, MSCE, discusses current data surrounding BTK inhibitors in chronic lymphocytic leukemia, the benefits of targeted therapies in this population, ways to begin addressing unmet needs, and the importance of improved clinical trial designs for varying patient populations.
May 2nd 2022
The time-limited combination of ublituximab and umbralisib plus ibrutinib resulted in an undetectable minimal residual disease rate of 77% in patients with chronic lymphocytic leukemia, according to findings from a phase 2 trial (NCT04016805)
April 30th 2022
The combination of ceralasertib and acalabrutinib showed preliminary clinical activity with acceptable tolerability in patients with high-risk, relapsed/refractory chronic lymphocytic leukemia.
April 15th 2022
The pending biologics license application and supplemental new drug application seeking the approval of the combination of ublituximab and umbralisib in adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma has been voluntarily withdrawn by TG Therapeutics, Inc.
April 14th 2022
A small proportion of a subset of patients with chronic lymphocytic leukemia acquired mechanisms of genetic resistance to the novel noncovalent BTK inhibitor pirtobrutinib, according to results from a genomic analysis of patients in the phase 1/2 BRUIN trial.